Monoclonal Antibody Use in LTC Facilities
Monoclonal antibody (mAb) therapy are treatments that may reduce the risk of severe COVID19 disease and hospitalization. Monoclonal antibody treatment is indicated for persons with a positive COVID-19 test result, and for persons with a known exposure to COVID-19. The goal of this therapy is to reduce viral loads through neutralization of the COVID-19 virus, lessen symptom severity, and help prevent hospitalizations. Persons who may benefit from mAb treatments include those with risk factors for development of severe COVID-19 disease (below). Monoclonal antibody (mAb) treatments can currently be administered either by intravenous or subcutaneous routes.
Who is Eligible?
Adult or pediatric (>12 years of age and weighing at least 40 kg) patients at high-risk for progressing to severe disease or death.
Patients who are COVID-19 positive, with mild-to-moderate symptoms, not hospitalized due to COVID-19 symptoms, and not requiring oxygen or an increase in home oxygen therapy are eligible, regardless of vaccination status.
Post-Exposure Prophylaxis (PEP)
Individuals who are not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS- CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) and
- have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC or
- who are at high risk of exposure to an individual infected with SARS-CoV-2
Risk Factors for Development of Severe COVID-19 Include, but are not Limited to
(for both treatment and PEP indications)
- Older age (for example > 65 years of age)
- Obesity or being overweight (for example, adults with BMI ≥ 25, or if age 12-17, have BMI > 85th percentile for their age and gender based on CDC growth charts)
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital abnormalities)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of mAb therapy is not limited to the medical conditions or factors listed above. (For additional information on medical conditions and factors associated with increased risk for progression to severe COVID19, visit the CDC website).
Monoclonal Antibody Therapy Matchmaker
The Illinois Department of Public Health is deploying the Illinois COVID-19 Monoclonal Antibody (mAB) Matchmaker. The mAb Matchmaker will allow for facilities to redistribute mAb if the facility has excess doses or a facility is in need of doses.
Use this link: IL COVID-19 Monoclonal Antibody Matchmaker
- To redistribute mAb, please fill out the “Add mAb” column on the dashboard.
- To request mAb, please fill out the “Request mAb” column on the dashboard.
Note: The “Row ID” is the most important field to complete when requesting mAb. Please double check the Row ID before submitting your request to ensure you have selected the correct row.
- To remove your listing, please enter the Row ID and ask for 0 doses. When you refresh the page your listing will be removed.
When a match is made both facilities will be notified by email with contact information and the amount requested. The two matched facilities will coordinate the transfer of mAb.
A facility will also receive an email if only part of the listing was requested. The facility will have the opportunity to add those doses back to the matchmaker or keep the mAb doses internal.
If you have any other questions, please contact firstname.lastname@example.org.